Therapeutic value of somatostatin and nitroglycerin for prevention of post-ERCP pancreatitis
10.3760/cma.j.issn.1007-5232.2014.04.007
- VernacularTitle:生长抑素和硝酸甘油预防经内镜逆行胰胆管造影术后胰腺炎的疗效观察
- Author:
Xiaojian HE
;
Zhijian ZHANG
;
Dazhou LI
;
Jianqiang LIU
;
Haitao LI
- Publication Type:Journal Article
- Keywords:
Cholangiopancreatography,endoscopic retrograde;
Pancreatitis;
Hyperamylasemia;
Somatostatin;
Nitroglycerin
- From:
Chinese Journal of Digestive Endoscopy
2014;31(4):206-209
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the preventive effect of somatostatin and nitroglycerin on post-ERCP pancreatitis (PEP) and hyperamylasemia.Methods A total of 184 patients who underwent endoscopic retrograde cholangiopancreatograph (ERCP) were enrolled,and randomly divided into three groups to receive somatostatin or nitroglycerin or normal saline according to random number table.Incidence of PEP and hyperamylasemia were observed and compared among the three groups.Results Nine patients stopped the medication and dropped out of the study after occurence of adverse reactions from receiving nitroglycerin injections.The incidence rates of hyperamylasemia were 38.7％ (24/62),51.8％ (28/54) and 37.3％ (22/59) in somatostatin,nitroglycerin and control group respectively,with no significant differences among the three groups (P ＞ 0.05).The incidence rates of PEP were 6.4％ (4/62),9.3 ％ (5/54) and 23.7％ (14/59) in somatostatin,nitroglycerin and control group,respectively.The incidence rates of PEP in somatostatin and nitroglycerin group were both significantly lower than that in control group (somatostatin group vs control group:x2 =7.13,P =0.01 ; nitroglycerin group vs control group:x2 =4.22,P =0.03).There was no significant difference between somatostatin group and nitroglycerin group (x2 =0.32,P =0.41).Conclusion Somatostatin and nitroglycerin injections after ERCP show similar efficacy on preventing PEP,but the former is safer.Both have little effects on the prophylaxis of hyperamylaemia.
